Small RNA Transfection: How Small Players Can Make a Big Impact

Posted on by Simon Moe

When looking at small aspects of living things, especially cells, it can often be difficult to fully grasp the magnitude of regulation employed within them. We first learn the central dogma in high school biology. This is the core concept that DNA makes RNA and RNA makes protein. Despite this early education, it can be lost on many the biological methods that are employed to regulate this process. This regulation is very important when one considers the disastrous things that can occur when this process goes askew, such as cancer, or dysregulated cell death. Therefor it is very important to understand how these regulatory mechanisms work and employ tools to better understand them.

Continue reading “Small RNA Transfection: How Small Players Can Make a Big Impact”

For Frogs, Surviving the Heat Could Come Down to What Is in Their Gut

Posted on by Kelly Grooms

Amphibians are the most threatened vertebrate class worldwide. Because they lack the ability to regulate their own temperature and moisture levels, climate change is playing a significant role in this growing peril (1). Climate change impacts amphibian survival in several ways. In addition to habitat loss, growing drought conditions make maintaining body moisture levels challenging and warming temperatures restrict activity periods needed for reproduction as well as increasing the risk of heat stress.

Heat tolerance varies by species, and understanding what influences these differences could help predict species survival. The gut microbiota is known to affect a wide range of functions in host animals, and recently studies have begun to investigate its role in host thermal tolerance (2).

Continue reading “For Frogs, Surviving the Heat Could Come Down to What Is in Their Gut”

Treating Solid Tumors: Combining CAR-T Cell Therapy with Probiotics

Posted on by Johanna Lee

Chimeric Antigen Recepter (CAR)-T cell therapy is a personalized immunotherapy that harnesses the patient’s own immune system to combat cancer. It is done by engineering the patient’s T cells to specifically target and attack cancer cells in their body, and it has shown great success in treating various blood cancers such as leukemia.

Treating solid tumors with CAR-T cells, however, has proved much more challenging. This is mainly because solid tumors contain a heterogeneous population of cells, expressing a variety of antigens—many of which are also expressed in healthy cells. Therefore, T cells targeting solid tumors could potentially attack healthy tissue, resulting in serious side effects. In addition, solid tumors create a hostile microenvironment that is difficult for CAR-T cells to infiltrate.

Continue reading “Treating Solid Tumors: Combining CAR-T Cell Therapy with Probiotics”

Promega qPCR Grant Series #3: Immunotherapy Researcher, Dr. Sabrina Alves dos Reis 

Posted on by Anna Bennett
Professional headshot image of Dr. Sabrina Alves dos Reis, subject of the blog post
Sabrina Alves dos Reis

In our third and final installment of the Promega qPCR Grant Recipient blog series, we highlight Dr. Sabrina Alves dos Reis, a trained immunotherapy researcher. Her work has focused on developing tools for more accessible cancer therapies using CAR-T cells. Here, we explore Dr. Alves dos Reis’ academic and scientific journeys, highlight influential mentorship and foreshadow her plans for the Promega qPCR grant funds. 

Dr. Alves dos Reis’ career began with a strong affinity for biology. As an undergraduate student, she pursued a degree in biological science, where she developed a foundational understanding for designing and developing research projects. As her passion for science heightened, she decided to continue her journey in science, culminating in a PhD at the Fundação Oswaldo Cruz Institute in Rio de Janeiro, Brazil. Her research projects focused on the unexplored territory of adipose tissue as a site for Mycobacterium leprae—or leprosy bacillus—infection. She mentioned that this work piqued her curiosity for improving immunotherapies and laid the foundation for her future in cancer research.  

Continue reading “Promega qPCR Grant Series #3: Immunotherapy Researcher, Dr. Sabrina Alves dos Reis “

Elevate Your Research: Exploring the Power of 8-Dye STR Chemistry with the Spectrum Compact CE System

Posted on by Promega

In genetic research, staying at the forefront of technology is crucial. The latest breakthrough in human identification comes in the form of 8-dye Short Tandem Repeat (STR) chemistry. This innovation promises unprecedented precision and accuracy in DNA analysis, revolutionizing the way we approach genetic studies. In this blog post, we’ll delve into the world of 8-color chemistry and explore how it seamlessly integrates with the game-changing Spectrum Compact CE System.

Understanding 8-Dye STR Chemistry

The introduction of 8-dye chemistry expands the capability of STR analysis, enabling researchers to analyze more DNA markers with smaller amplicons, providing more robust data from degraded or inhibited DNA samples.  The performance of the 8-color dye chemistries from Promega on the Spectrum Compact CE System is sensitive, with both chemsitries (PowerPlex® 35 GY System and the upcoming PowerPlex® 18 E System) producing 100% profiles from their suggested inputs down to as little as 62.5 pg of DNA. The 18E system produced 100% profiles down to 31.25 pg of input DNA with minimal signal bleed through and low system noise.

Table showing percent STR profiles generated with decreasing input DNA using the PowerPlex 35GY or PowerPlex 18 E chemistry on the Spectrum Compact CE System
Table showing percent profiles generated with decreasing input DNA using the PowerPlex® 35GY or PowerPlex® 18E chemistry on the Spectrum Compact CE System.
Continue reading “Elevate Your Research: Exploring the Power of 8-Dye STR Chemistry with the Spectrum Compact CE System”

Custom in vitro Transcription Reagents for Manufacturing RNA Therapeutics

Posted on by AnnaKay Kruger
Doctor filling syringe

Research into vaccines based on RNA began decades ago when scientists theorized that they could harness RNA to produce viral proteins within a cell, prompting a protective immune response. RNA vaccine research drew scientists’ attention during the development of SARS-CoV-2 vaccines during the COVID-19 pandemic, which opened the door for research targeting other diseases with RNA-based therapeutics.

Continue reading “Custom in vitro Transcription Reagents for Manufacturing RNA Therapeutics”

The R&D Flex Team: A Unique Research Scientist Opportunity

Posted on by Jordan Villanueva

Sarah Mahan embraces change. In fact, she doesn’t just embrace it, she seeks it out, running towards change with arms wide open. 

“If I could do a different thing every week, I would. That’s what my job would be.”

Sarah made her dream a reality when she began leading the Promega R&D Flex Team. This group of diverse research scientists moves around Kornberg Center, contributing resources to accelerate the development of technologies like Lumit Immunoassays and PowerPlex chemistry. They don’t specialize in any field or technology, but rather are constantly challenged to learn new skills quickly. Everywhere they go, they help R&D teams generate more data, answer more questions, and deliver results in less time.

“In short,” Sarah says, “we’re helping research teams make better products, faster.”

Continue reading “The R&D Flex Team: A Unique Research Scientist Opportunity”

Insights from our Second Annual Targeted Protein Degradation Symposium

Posted on by Jordan Nutting

In the opening remarks of our second annual Targeted Protein Degradation Symposium, Tom Livelli, VP of Life Sciences Products & Services at Promega, posed a question to the attendees: “What do you want to be able to do today that you can’t?” This aspirational question set the tone for an event where building connections to advance the study and application of proximity-induced degradation took center stage.

More than 90 attendees from academia and industry gathered September 20–21 for the two-day symposium, which was hosted in our inspirational Kornberg Center—the R&D heart of Promega. Through engaging talks, a poster session, “Learn n’ Burn” challenges and social gatherings, participants had the opportunity to reinforce existing collaborations and to connect with others who are making an impact in the field of targeted protein degradation.

Continue reading “Insights from our Second Annual Targeted Protein Degradation Symposium”

World Mental Health Day: Prioritizing Wellness in the Workplace

Posted on by Riley Bell

Celebrated annually on October 10th, World Mental Health Day provides an opportunity for people and communities to improve knowledge, raise awareness, and mobilize efforts in support of mental health.

Many people find that working is beneficial for their mental health. Having a job can help provide financial stability, establish a structured routine, improve one’s sense of identity, and more. However, at times your work may negatively impact your mental health and vice versa. Read some tips on how you can enhance your workplace well-being and cultivate a happier professional life.

Continue reading “World Mental Health Day: Prioritizing Wellness in the Workplace”

Glowing Testimonies: A Review of NanoLuc® Use in Model Organisms

Posted on by Kerstin Hurd
NanoLuc®

Model organisms are essential tools in the pursuit of understanding biological processes, elucidating the mechanisms of diseases, and developing potential treatments and therapies. Use of these organisms in scientific research has paved the way for groundbreaking discoveries across various fields of biology. In particular, non-mammalian models can be valuable due to characteristics such as rapid life cycles, low cost, and amenability to use with advanced genetic tools, including bioluminescent reporters such as NanoLuc® Luciferase.

NanoLuc® is a small (19.1 kDa) luciferase enzyme originating from deep sea shrimp that is 100x brighter than firefly or Renilla luciferase. It utilizes a furimazine substrate to produce its bright glow-type luminescence. In the decade following its development, the NanoLuc® toolbox has expanded to include NanoBiT® complementation, NanoBRET™ energy transfer methods, and new reagents such as the Nano-Glo® Fluorofurimazine In Vivo Substrate (FFz) which was designed for in vivo detection of NanoLuc® Luciferase, NanoLuc® fusion proteins or reconstituted NanoBiT® Luciferase. In addition to the aqueous-soluble reagents increased substrate bioavailability in vivo, with fluorofurimazine, NanoLuc® and firefly luciferase can be used together in dual-luciferase molecular imaging studies.

Here we spotlight some recent research that demonstrates how the expanded NanoLuc® toolbox can be adapted to use in non-mammalian models, shedding new light on fundamental biological processes and advancing our understanding of complex mechanisms in these diverse organisms.

Continue reading “Glowing Testimonies: A Review of NanoLuc® Use in Model Organisms”